PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Loteprednol etabonate - Post-op ocular inflammation

PAD Profile : Loteprednol etabonate - Post-op ocular inflammation

Keywords :
steroid, short term, eye drops
Brand Names Include :
Lotemax

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Eye drops
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
01 March 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) agrees that loteprednol etabonate eye drops  should only be used on a short-term basis (maximum of 2 weeks duration) to treat post-operative inflammation as per its product license.

Therefore, loteprednol etabonate  a RED traffic light status is agreed by APC.

Sufficient quantities should be supplied through secondary care as part of a package of post-operative care.”

Associated BNF Codes

11. Eye
11.04.01. Corticosteroids
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More